BioCryst Pharmaceuticals Reports Director/Officer Changes & More
Ticker: BCRX · Form: 8-K · Filed: Jun 16, 2025 · CIK: 882796
Sentiment: neutral
Topics: corporate-governance, executive-changes, shareholder-matters, financials
Related Tickers: BCRX
TL;DR
BioCryst shuffled execs and directors, filed financials, and held a shareholder vote.
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting events as of June 11, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes the submission of matters to a vote of security holders and financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate governance and executive changes at BioCryst Pharmaceuticals, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can signal internal shifts that may affect company performance and strategy.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- June 11, 2025 (date) — Earliest event reported
- June 16, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Durham, North Carolina (location) — Principal executive offices
FAQ
What specific items were reported under 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'?
The filing indicates that these events occurred, but the specific details of departures, elections, appointments, and compensatory arrangements are not provided in this summary section of the 8-K.
What matters were submitted to a vote of security holders?
The filing confirms that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.
What types of financial statements and exhibits are included in this filing?
The filing states that Financial Statements and Exhibits are included, but the specific content of these exhibits is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 11, 2025.
What is BioCryst Pharmaceuticals, Inc.'s principal executive office address?
BioCryst Pharmaceuticals, Inc.'s principal executive office is located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).